Fulminant liver failure in a patient treated with Sunitinib for metastatic gastrointestinal stromal tumor

Gastroenterol Hepatol. 2021 Jun-Jul;44(6):424-425. doi: 10.1016/j.gastrohep.2020.08.006. Epub 2020 Nov 10.

[Article in English, Spanish]

Authors

Diego Casas Deza¹, Marta Gascón Ruiz², Luis Javier Lamuela Calvo³, Olivia Sierra Gabarda³, Elena Betoré Glaria³, Vanesa Bernal Monterde³

Affiliations

¹ Servicio de Aparato Digestivo, Hospital Universitario Miguel Servet, Zaragoza, España. Electronic address: diegocasas8@gmail.com.
² Servicio de Oncología Médica, Hospital Clínico Lozano Blesa, Zaragoza, España.
³ Servicio de Aparato Digestivo, Hospital Universitario Miguel Servet, Zaragoza, España.

PMID: 33187743
DOI: 10.1016/j.gastrohep.2020.08.006

No abstract available

Publication types

Case Reports

MeSH terms

Aged
Antineoplastic Agents / adverse effects*
Antineoplastic Agents / therapeutic use
Fatal Outcome
Gastrointestinal Neoplasms / drug therapy*
Gastrointestinal Neoplasms / pathology
Gastrointestinal Stromal Tumors / drug therapy*
Gastrointestinal Stromal Tumors / secondary
Humans
Imatinib Mesylate / therapeutic use
Liver Failure, Acute / chemically induced*
Liver Neoplasms / secondary
Male
Sunitinib / adverse effects*

Substances

Antineoplastic Agents
Imatinib Mesylate
Sunitinib